Skip to main content
. Author manuscript; available in PMC: 2022 May 9.
Published in final edited form as: Crit Care Med. 2019 Mar;47(3):e173–e181. doi: 10.1097/CCM.0000000000003559

Figure 1.

Figure 1.

The mean change from baseline in Pediatric Logistic Organ Dysfunction (PELOD) score by treatment group (60 therapeutic plasma exchange [TPE]-treated thrombocytopenia-associated multiple organ failure [TAMOF] patients and 21 standard therapy–treated TAMOF patients). Time trend lines are the model-based means and 95% CIs. The vertical bars are the 95% CIs. Change from baseline in PELOD scores in the two treatment groups differed in temporal pattern during the first week on study (p = 0.009, test for interaction between time on study and treatment group). By day 4, the mean PELOD had declined by 7.9 points (95% CI, −10.8 to −5.1) in the TPE-treated group, but the mean PELOD score did not change over time in the no TPE group (p = 0.40, test for linear trend).